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Jeremiah William Hendricks 
INHIBITING PROTEIN CLEARANCE TO INDUCE CELL DEATH IN TUBEROUS SCLEROSIS AND 
PANCREATIC CANCER 
 
 Sequestration at the aggresome and degradation through autophagy are two 
approaches by which a cell can counteract the toxic effect of misfolded proteins. 
Tuberous sclerosis (TS) and cancer cells can become dependent on autophagy for 
survival due to the high demand for protein synthesis, thus making protein clearance a 
potential therapeutic target. Because of its histone deacetylase (HDAC) inhibitory 
activity, we hypothesized that 4-phenylbutyrate (4-PBA) inhibits HDAC6 and aggresome 
formation to induce TS cell death. We found that 4-PBA treatment increases cell death 
and reduces bortezomib-induced aggresome formation. To link these results with HDAC 
inhibition we used two other HDAC inhibitors, trichostatin A (TSA) and tubastatin, and 
found that they also reduce bortezomib-induced protein aggregation. Because tubulin is 
a target of HDAC6, we next measured the effect of the HDAC inhibitors and 4-PBA 
treatment on tubulin acetylation. As expected, tubastatin increased tubulin acetylation 
but surprisingly TSA and 4-PBA did not. Because 4-PBA did not significantly inhibit 
HDAC6, we next hypothesized that 4-PBA was alternatively inducing autophagy and 
increasing aggresome clearance. Surprisingly, autophagy inhibition did not prevent the 
4-PBA-induced reduction in protein aggregation. In conclusion, we found 4-PBA to 
induce cell death and reduce aggresome levels in TS cells, but we found no link between 
these phenomena. We next hypothesized that loss of the Ral guanine nucleotide 
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exchange factor Rgl2 induces cell death via autophagy inhibition in pancreatic 
adenocarcinoma (PDAC) cells. KRas is mutationally activated in over 90% of PDACs and 
directly activates Rgl2. Rgl2 activates RalB, a known regulator of autophagy, and Rgl2 
has been shown to promote PDAC cell survival. We first confirmed that loss of Rgl2 does 
increase cell death in PDAC cells. Initial experiments using doubly tagged fluorescent 
p62 and LC3 (autophagy markers) suggested that loss of Rgl2 inhibited autophagosome 
accumulation, but after developing a more sophisticated quantitation method we found 
loss of Rgl2 to have no effect. We also measured endogenous LC3 levels, and these 
experiments confirmed loss of Rgl2 to have no effect on autophagy levels. Therefore, 
loss of Rgl2 increases cell death in PDAC cells, but does not have a significant effect on 
autophagy.  
 
Lawrence A. Quilliam, PhD, Chair 
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CHAPTER 1. INTRODUCTION 
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1.1 Introduction to cancer signaling 
 
Signal transduction pathways communicate external stimuli via a series of 
proteins to elicit a response from the cell. These external stimuli can be other protein 
ligands, changes in ion concentration, or even physical stress [1-3]. The external 
stimulus is recognized by a membrane receptor and communicated to the interior of the 
cell by a series of second messengers [4]. Responses of cells can include changes in 
protein expression, cell growth, or alternatively initiation of apoptosis [5-7]. A number 
of gene mutations that transition a normal cell to a cancer cell often interrupt a normal 
signaling pathway [8]. The two main types of mutated genes in cancer are tumor 
suppressors that inactivate otherwise protective genes and oncogenes that will drive 
the growth of a tumor. The mutationally activated KRAS is considered an oncogene 
because it drives PDAC tumorigenesis and progression [9]. Mutant KRas drives Ras 
signaling even in the absence of stimulus. TSC1 and TSC2, on the other hand, normally 
signal to mTOR to slow protein production [10]. TSC is therefore considered a tumor 
suppressor syndrome because mutated TSC1 and TSC2 cannot inhibit unrestrained cell 
growth. Tumor cells take advantage of mutations in signaling proteins to always 
maintain a pro-growth signal and ignore anti-growth and pro-death stimuli. 
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1.2 Small GTPase signaling 
 
Small GTPases are a type of guanine nucleotide-binding proteins which bind to 
guanosine triphosphate (GTP) and hydrolyze it into guanosine diphosphate (GDP) via 
their intrinsic GTPase activity. While approximately 150 small GTPases exist in the 
human body, the prototype and best characterized example of a small GTPase is Ras 
[11]. The activity of a small GTPase is dictated by being bound to GTP, “on” state, or 
GDP, “off” state. When bound to GTP, small GTPases typically undergo a conformation 
change that creates a binding surface otherwise not present when the GTPase is bound 
to GDP. For example, when Ras is bound to GTP it can interact with a number of 
effectors, such as Raf, and localize them to the plasma membrane [12]. The intrinsic 
hydrolysis of GTP to GDP by a small GTPase is catalyzed by a GTPase activating protein 
(GAP) [13]. When a GAP is bound to a small GTPase, the catalytic machinery of the 
GTPase is stabilized and allows for quicker hydrolysis. One example of a GAP is 
neurofibromin (encoded by the Nf1 tumor suppressor locus), which catalyzes hydrolysis 
of RasGTP to RasGDP, thus turning Ras-directed signaling “off” [14].  
The counterparts to GAPs are guanine nucleotide exchange factors (GEFs). When 
GEFs bind to GDP bound small GTPases, the binding conformation causes a quick release 
of GDP [15]. Because GTP is found at a higher concentration in the cytosol relative to 
GDP, a GTP will rapidly bind and take the GDP’s place, displacing the GEF in the process. 
Therefore, GEF’s have the capability to turn a small GTPase “on”. One GEF of Ras is Son 
of Sevenless-1(SOS1) which is first recruited to the plasma membrane by EGFR where it 
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can then activate Ras [16]. Small GTPase signaling is a unique molecular mechanism for 
transmitting a signal and many different small GTPase pathways are important in tumor 
cell signaling.  
 
1.3 Ras family proteins 
 
The Ras family of proteins play an important role in cancer signaling, about 20% 
of all human cancers have an activating mutation in a Ras gene [17]. The Ras proteins 
get their name from rat sarcoma viruses, a reflection of their discovery that when the 
cellular activated Ras was encoded in retroviruses it elicited tumors in infected rodents 
[18]. HRas, NRas, and KRas, the three primary Ras proteins, have about 85% sequence 
identity and are all found with activating mutations in tumors [17]. All three of these 
proteins are widely expressed with KRas being almost ubiquitous. Ras proteins are first 
farnesylated at a C-terminal CaaX box, the aaX residues are cleaved off and then the 
COO- group of the terminal cystein is methylated to allow attachment into the plasma 
membrane. Membrane attachment is also facilitated in NRas and HRas via subsequent 
palmitoylation of adjacent Cys residues, or in the case of KRas via a polybasic sequence 
adjacent to the prenylation site that binds negative phospholipids [19]. Localization to 
the inner surface of the plasma membrane is required for normal function of the Ras 
proteins. This has been shown by mutagenesis or inhibition of the above post-
translational events. Once properly localized and activated, Ras proteins signal to a 
number of downstream signaling pathways to promote cellular proliferation.  
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A number of other proteins also belong to the Ras family. Rap proteins, originally 
named Ras proximate, regulate cell-cell and cell-matrix adhesion [20]. The Rap proteins 
include Rap1A, Rap1B, Rap2A, Ralp2B, and Rap2C. Mutationals that activate Rap 
proteins do not typically cause transformation and can actually inhibit Ras 
transformation via competition for effectors or by promoting growth inhibitory cellular 
changes [21]. Other members of the Ras family are the Ras-like proteins, RalA and RalB. 
Ral proteins are directly downstream of Ras and play a dominant role in Ras-mediated 
transformation in human cell lines [22]. The Ral proteins will be a topic of further 
discussion in Section 1.8. Another notable Ras family protein is Ras homolog enriched in 
brain (Rheb) that regulates growth and cell cycle regulation by activating mTOR. Despite 
its name, Rheb is ubiquitously expressed and is the protein that TSC1/2 directly inhibit 
to suppress mTOR signaling (TSC is the Rheb GAP). Ras family proteins play a number of 
direct roles in tumorigenesis by regulating cell growth and proliferation. 
 
1.4 KRas effectors 
 
 KRas signals to three main downstream pathways: Raf/MEK/ERK, 
PI3K/Akt/mTOR, and RalGDS/Ral (Figure 1-1). The best characterized of these is the 
Raf/MEK/ERK pathway. The Raf (rapidly accelerated fibrosarcoma)/MEK (mitogen-
activated protein kinase/ERK kinase)/ERK (extracellular-signal-regulated kinase) 
pathway is also known as a mitogen-activated protein kinase (MAPK) cascade and 
controls such fundamental processes as proliferation, differentiation, survival, and 
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apoptosis [23]. Raf binds to Ras-GTP, which localizes it to the membrane where it can 
then be phosphorylated [24]. This activation then permits Raf to phosphorylate MEK 
which in turn phosphorylates ERK [25]. Activated ERK is localized to the membrane and 
especially the nucleus where it can convert the MAPK signal into biological effect by 
enhancing gene expression via increasing DNA availability and phosphorylating 
transcription factors [26]. The role of the MAPK cascade in cancer is enhanced by 
aberrant upstream activation, such as mutated KRas, and can include inhibition of cell 
death [27].  
Another well characterized pathway downstream of KRas is PI3K/Akt/mTOR. Ras-
GTP binds to phospoinositide 3-kinase (PI3K) and increases its kinase activity [28]. PI3K 
is a lipid kinase that phosphorylates the 3’-hydroxyl group of phosphoinositides. One 
product of this reaction is phosphatidylinositol-3,4,5-triphosphate, (PIP3) which then 
recruits Akt to membranes for phosphorylation by phosphoinositide-dependent kinase 1 
(PDK1) [29, 30]. Phosphorylation of Akt stimulates its own catalytic activity, resulting in 
the phosphorylation of a number of targets including TSC2. Phosphorylation of TSC2 
prevents its inhibition of Rheb and consequently mTOR which then permits proliferation 
and cell cycle progression [31]. This pathway plays important roles in many cancers. It 
has been shown that PI3K is necessary and sufficient to maintain RAS-transformed 
xenograft tumors after the loss of Ras [32]. Also, AKT2 is amplified in 20% of PDAC 
tumors [33]. Activated KRas stimulates tumor growth through both the MAPK cascade 
and the PI3K/Akt/mTOR pathway. 
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Figure 1-1. KRas signals to effectors PI3K, Raf, and RalGEFs triggering a number of 
cellular responses 
 
Ras-GDP is converted to Ras-GTP by RasGEFs such as SOS, which is localized to the 
plasma membrane via ligand activation of receptors such as EGFR. Activated Ras-GTP 
binds to various effectors including PI3K, RalGDS proteins, and Raf. These signaling 
pathways activate multiple cellular responses including survival, transformation, and 
proliferation. 
 
 
 
 
 
Image reproduced from: Normanno, Tejpar [34]  
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1.5 Ral signaling 
 
A third, less characterized pathway downstream of KRas is the RalGEF/Ral 
pathway. The two Ral proteins, RalA and RalB, are small GTPases activated by RalGEFs 
and deactivated by RalGAPs. The Ral guanine nucleotide dissociation stimulator 
(RalGDS) family is a group of RalGEFs that bind to Ras-GTP via their Ras binding domain 
(RBD) and then exchange Ral-GDP for Ral-GTP [35]. The RalGDS family consists of 
RalGDS, RalGDS-like (Rgl), Rgl2, and Rgl3. RalGPS1a, GPS1b, and RalGPS2 are also 
RalGEFs but do not interact with Ras. However, these RalGEFs do contain pleckstrin 
homology (PH) domains and SRC homology 3 (SH3) binding motifs which may substitute 
for Ras-mediated membrane recruitment/GEF activation [36]. Ral-GTP then activates an 
effector such as Ral binding protein 1 (RalBP1) which regulates actin dynamics and 
endocytic pathways [37, 38]. Activated Ral also targets Sec5 and Exo84, two 
components of the exocyst [39, 40]. The exocyst is a multiprotein complex that 
regulates vesicle targeting, from the Golgi to the basal-lateral membrane for example 
[41].  RalGAP1 and RalGAP2 deactivate Ral by catalyzing the hydrolysis of GTP to GDP 
[42].  
Despite sharing 85% amino acid sequence identity, recent work has suggested 
that RalA and RalB have distinct functions [43]. Loss of RalA but not RalB has been 
shown to reduce transformed and tumorigenic growth in pancreatic cancer cells [44]. 
This study also showed that RalB but not RalA is crucial for tumor cell invasion and 
metastases in mice [44]. These results were recently echoed in another research artice 
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that showed loss of RalA but not RalB decreased anchorage-independent growth in 
colorectal cells [45]. Surprising, this same study found that RalA and RalB have 
antagonistic effects; overexpression of RalB also inhibited anchorage-independent 
growth [45].  
Another study has shown that RalA and RalB both regulate the exocyst at 
different stages of cytokinesis during mitosis. It was suggested that these distinct 
functions are dictated by divergent localization [46]. This hypothesis is strengthened by 
an earlier report that RalA is found at the plasma membrane and RalB on endosomes 
[47]. It has been suggested that RalA and RalB achieve divergent localization via post-
translational modifications [48]. Even in light of these hypotheses, it is still not 
completely clear how RalA and RalB achieve distinct functions.  
There has been some discussion over whether the many different RalGEFs are 
redundant or if they have unique functions. Protein kinase A (PKA) phosphorylates Rgl2 
at Ser737, reducing its ability to bind HRas. This phosphorylation site is not conserved 
among RalGDS, Rgl, or Rgl3 [49], and therefore this modification scheme could be one 
mechanism of imparting unique functions to Rgl2. Another possible means of 
delineating functions among the RalGEFs could be different cell localizations. During 
cytokinesis, it was found that RalGDS specifically colocalizes with RalA whereas Rgl 
colocalizes with RalB [46]. Furthermore, Rgl2 has been found to colocalize with RalB at 
the leading edge of PDAC cells and be required for RalB to be situated there [50]. 
Differential expression is a third mechanism that could instill different functions for 
RalGEFs. In the PDAC cell lines SW-1990, MIA-PACA-2, CFPAC-I, AsPC-1, BxPC-3, and 
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Capan-1, it was found that RalGDS and Rgl2 are more highly expressed than Rgl and Rgl3 
[50]. Rgl2 was also shown to be required for anchorage-independent growth in these 
cells. There is not sufficient evidence yet to determine if the six RalGEFs are redundant 
or have unique function. 
 
1.6 mTOR signaling 
 
TOR was originally discovered in yeast as the target of rapamycin, an anti-
mycotic compound discovered in bacteria isolated from the soil of the island Rapa Nui 
[51]. Its mammalian homologue, mTOR, is the catalytic subunit of the rapamycin 
sensitive mTOR complex 1 (mTORC1) and the rapamycin insensitive mTORC2 [52] 
(Figure 1-2). The other elements of mTORC1 and mTORC2 include PRAS40, GβL, and 
debtor. mTORC1 also includes a phosphorylation-dependent regulator protein named 
raptor, while mTORC2 has a similar substrate-binding protein named rictor [53]. 
mTORC1 is primarily responsible for activating protein synthesis by phosphorylating 
ribosomal S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E-binding 
protein 1 (4EBP1). When S6K1 is phosphorylates it activates the ribosomal protein S6 
that stimulates mRNA translation [54]. 4EBP1 phosphorylation, on the other hand, 
facilitates the activity of eIF4F complex, a key component of mRNA translation [55]. The 
small GTPase Rheb drives mTOR activity by recruiting it to the cytoplasmic surface of 
lysosomes [56]. TSC2 inhibits the activity of Rheb by acting as a RhebGAP, catalyzing the 
hydrolysis of GTP to GDP [57]. TSC2 acts as a signaling hub in regulation of mTOR. In 
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addition to being negatively regulated by Akt, TSC2 and TSC1 are also inhibited by ERK 
and IKKβ respectively, while TSC2 is activated by AMPK and GSK3β [58]. In both TSC2-
null diseases and PDAC, mTOR signaling is increased and protein expression is amplified.  
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Figure 1-2. mTOR is regulated by a number of upstream signaling events to regulate 
protein synthesis and autophagy 
 
The TSC1 and TSC2 complex is a RhebGAP that deactivates Rheb activity by catalyzing 
the hydrolysis of bound GTP to GDP. Various signaling proteins including ERK and Akt 
deactivate TSC1/2 via phosphorylation facilitating Rheb activity. Meanwhile 
phosphorylation of TSC2 by AMPK stimulates its GAP activity. Once active, Rheb can 
bind and activate mTOR which drives mRNA translation via phosphorylation of S6K and 
4E-BP. mTOR also inhibits autophagy by phosphorylating Ulk, inhibiting autophagosome 
assembly. 
 
 
Image reproduced from: Wullschleger, Loewith [59] 
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1.7 Introduction to pancreatic cancer  
 
Pancreatic cancer is one of the most difficult  cancers to effectively treat,   with 
only 6% of afflicted patients  surviving five years after diagnosis[60]. Unfortunately, little 
progress has been made in pancreatic cancer treatment since 1975; the five year 
survival rate has only increased from 2% to 6%  since that time, compared with an 
increase from 49% to 68% survival  among all cancers combined [60]. The incidence of 
pancreatic cancer is low to moderate, with 45,220 estimated new cases in 2013, but has 
a high mortality rate with 38,460 estimated deaths [61]. Some non-genetic risk factors 
for pancreatic cancer include cigarette smoking, obesity, and chronic pancreatitis [60]. 
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic 
cancer and is the fourth leading cause of cancer death in the United States [62]. PDACs, 
which get their name from a histological resemblance to ductal cells, are believed to be 
preceded by pancreatic intraepithelial neoplasias (PanINs) which are common in older 
adults and have been found in as many as 30% of patients [62]. Currently the standard 
treatments for pancreatic cancer are the DNA damaging agent, gemcitabine, and the 
EGFR inhibitor, erlotinib. Early clinical trials using a combination of gemcitabine and 
erlotinib increased the median survival by a fraction of a month and were considered a 
success [63]. However, due to the high mortality rate and low success of this therapy, 
much more research is required to develop effective therapies for pancreatic cancer. 
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1.8 PDAC biology and common mutations 
 
The histological progression of a normal pancreas cell to a PDAC cell has been 
well studied and defined. The origin of this disease is two cell types in the pancreas 
including exocrine acinar cells, that produce digestive enzymes, and ductal cells, which 
form the ducts that transport the enzymes. Recent studies have found that the initial 
stage of pancreatic tumor formation is transdifferentiation of cells from an acinar 
phenotype to a ductal one, a process known as acinar-to-ductal metaplasia (ADM) [64]. 
These transdifferentiated cells can then develop into PanINs which exhibit dysplastic 
growth and are graded from stages I to III, III being the stage of most extreme 
architectural disorganization [62]. Late stage PanINs then progress to PDAC, which is 
characterized by a dense stroma of fibroblasts and inflammatory cells and exhibit a 
glandular pattern with duct-like structures and some degree of cellular atypia [62]. 
PDAC cells have a great potential for metastasis due, at least in part, to the hypoxic 
microenvironment of the tumor, and there is even evidence for metastasis of early stage 
PanINs [65]. Such early metastatic events make PDAC a difficult disease for both early 
diagnosis and treatment. 
There are a number of common genes that are mutated and as a consequence 
activated or repressed in pancreatic tumors. SMAD4, TP53, p16, and KRAS are altered in 
at least 55% of PDACs [60]. For example, SMAD4  binds to the Smad binding elements 
(Sme) within the responsive elements of TGFβ responsive genes, repressing 
transcriptional expression. The resulting increased TGFβ signaling inhibits cell growth 
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and promotes differentiation; therefore, defective mutations in SMAD4 promote tumor 
growth [66]. Mutations in SMAD4 occur in 55% of patient samples. Mutations in TP53 
appear to arise in later stage PanINs and occur in more than 50% of patient samples 
[62]. Loss of functional p53 promotes the growth and survival of tumor cells with DNA 
damage. p16, another gene commonly inactivated in PDAC, encodes the protein ARF 
which stabilizes p53. p16 is altered in many different cancers and is inactivated in 95% 
of PDAC patients. The most commonly mutated gene in PDAC is KRAS, with more than 
90% of patients having mutations. Unlike the other commonly mutated or inactivated 
genes, the common mutations in KRAS create a constitutively activated gene product. 
Activated KRas is an initiating step in PDAC and promotes tumor cell growth and survival 
[62]. Having a number of commonly altered genes creates a potential for therapeutically 
targeting PDAC that unfortunately has not yet been realized.  
 
1.9 TSC and LAM 
 
Tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM) are both 
diseases characterized by inactivating mutations in TSC1 or TSC2. These mutations cause 
constitutive activity in mammalian target of rapamycin (mTOR), which will induce 
excessive protein synthesis. TSC is characterized by the formation of harmartomas, 
benign malformations, in multiples tissues and the rate of birth incidence is about 1 in 
6000 [67]. About 90% of patients with TSC will develop dermatological abnormalities 
and 50-80% will develop renal lesions [67]. Patients with TSC can also develop 
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neurological abnormalities such as epilepsy or neurocognitive dysfunction. LAM is a 
cystic lung disease that primarily affects women. Patients with TSC can develop LAM, 
however LAM predominantly develops sporadically. Most noteworthy, malignant renal 
tumors develop in 63% of patients with sporadic LAM [68].  Recent clinical trials studied 
the use of sirolimus, an inhibitor of mTOR, to treat patients with TSC and LAM [69]. 
 
1.10 Therapeutic attempts at targeting KRas signaling  
 
Due to its abnormally high activity, many attempts have been made at 
therapeutically targeting KRas and its effectors in cancer. For KRas to function it must be 
modified by a farnesyltransferase in order to attach to the plasma membrane. Some of 
the most promising KRas-targeting work has been using farnesyltransferase inhibitors 
(FTI). Tipifarnib, an FTI, was tested in clinical trials in combination with gemcitabine but 
ultimately failed to provide promising results [70]. A suspected reason for the failure of 
FTIs is that KRas can be alternatively lipid modified by type I geranylgeranyltransferase. 
Inhibitors of this geranylgeranyltransferase are currently being studied in combination 
with FTIs [71]. There have also been promising studies focused on decreasing KRas 
expression in PDAC cells with small interfering RNAs (siRNAs), but these studies have not 
entered clinical trials [72].  
Much research has also targeted KRas effectors. Sorafenib is a Raf inhibitor 
approved for treatment of hepatocellular carcinoma and renal cell carcinoma. A recent 
Phase II trial of sorafenib in combination with gemcitabine did not show significant 
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activity in PDAC, however. CI-1040, a MEK inhibitor, also made it to Phase II trials in 
patients with lung, breast, colon, and pancreatic cancer but did not demonstrate 
enough antitumor activity to justify further study [73]. Temsirolimus, an mTOR inhibitor, 
is approved for use in renal cell carcinoma but also shows little activity in pancreatic 
cancer [74]. Much less research has been done with inhibiting Ral signaling compared to 
the Raf/MEK/ERK and PI3K/Akt/mTOR pathways [75]. Due to the lack of success at 
inhibiting the other components in KRas signaling, further research could reveal the 
potential of inhibiting Ral signaling in PDAC. 
 
1.11 Introduction to autophagy 
 
The word autophagy is derived from Greek meaning “self-eating”, and describes 
a process by which the cell generates metabolic substrates by degrading its own 
organelles and protein [76]. Autophagy can be triggered by a number of conditions 
including nutrient deprivation, hypoxia, protein aggregation, and ER stress [77]. As 
opposed to protein degradation through the proteasome, cytosolic components are 
degraded in the lysosome in autophagy. These components are delivered to the 
lysosome by double-membrane vesicles called autophagosomes. When an 
autophagosome binds with a lysosome, the drop in pH and contact with hydrolases 
results in degradation of the autophagosome’s contents [78].  
Many different selective types of autophagy have been discovered that target 
such specific organelles, such as the ER, mitochondria, and peroxisome [79]. The 
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inflammasome, a multiprotein complex activated after cellular infection or stress, and 
the aggresome, a complex of unfolded aggregated proteins, are both protein structures 
degraded via the autophagosome [80, 81]. These structures are degraded by basal 
nonspecific autophagy. The best characterized proteins responsible for targeting such 
structures to the autophagosome are p62 (sequestosome-1) and neighbor of BRCA1 
gene (NBR1). NBR1 and p62 both bind ubiquitinated cargo proteins and are selectively 
degraded by autophagy [82]. Autophagy is a vital process shown to be important in such 
physiological processes as adaptation to starvation, cell differentiation, and immunity 
[78]. 
 
1.12 The aggresome 
 
A newly synthesized protein must first be correctly folded in order to be 
functional. If a protein fails to fold or is misfolded it can aggregate and excessive protein 
aggregation is toxic to a cell [83]. Misfolded proteins are handled by a cell in one of 
three ways: refolding by a protein chaperone, degraded by the proteasome, or 
sequestered with other aggregates in a structure called the aggresome [84] (Figure 1-3). 
The aggresome is a pericentriolar structure composed of aggregated ubiquitinated 
proteins located at the microtubule organizing center (MTOC) [83]. Individual 
aggregated particles are generated throughout the cytosol and are then transported on 
microtubules to the aggresome via the motor protein dynein [85]. Aggregate cargo is 
recruited to the dynein motors by histone deacetylase 6 (HDAC6), due to its ability to 
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bind both polyubiquitinated misfolded protein and dynein [86]. HDAC6 is a part of the 
class II HDAC family and has been shown to both deacetylate tubulin and regulate 
microtubule-dependent cell motility [87]. Aggresome formation has also been found to 
be dependent on p62 [88]. Although chaperones and proteasomes are both recruited to 
the aggresome, it is believed that aggresomes are ultimately degraded through 
autophagy [89]. The degradation of aggresomes via autophagy is dependent on the 
interaction between p62 and microtubule-associated protein 1 light chain 3 (LC3) [88]. 
The aggresome permits cells to degrade large protein aggregates while under stressed 
conditions.  
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Figure 1-3. Aggregated proteins are delivered to a perinuclear region to form the 
aggresome 
 
Misfolded proteins can aggregate in the cytoplasm and become toxic to the cell. To 
prevent toxicity, misfolded proteins can be ubiquitinated and degraded via 
proteasomes. Toxicity can also be prevented by the sequestration of protein aggregates 
at the aggresome. The aggregates are ubiquitinated and delivered to the mitochondrial 
organizing center (MTOC)  by HDAC6. The aggresome is an accumulation of aggregated 
proteins and can be ultimately degraded via autophagy. 
 
 
 
 
 
 
Altered image reproduced from: Chin, Olzmann [90] 
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1.13 Molecular components of autophagosome formation 
 
There are three main stages that take place over the course of autophagosome 
maturation: a cup-shaped double membrane structure called the phagophore forms in 
the cytosol, the membrane elongates and closes to form a double membrane vesicle 
called the autophagosome, and finally the outer membrane fuses with the lysosome to 
enable degradation of the autophagosome’s contents [91]. Genetic analyses in yeast 
have revealed that over 30 genes are required for these processes, and these proteins 
were designated Atg1 to Atg35 [92]. The proposed initiating site for autophagosome 
assembly is the phagophore assembly site (PAS), a hybrid of the forming membrane and 
a subset of proteins required in all types of autophagy (called the core autophagy 
machinery) [93]. The generation of the phagophore requires Vps34 in complex with 
Beclin1, Atg14, and Vps15 to form PI3P; a complex whose activity is dependent on 
Ulk1/2, Atg13, and FIP200 [94] (Figure 1-4). The elongation of the phagophore then is 
regulated by two ubiquitination-like reactions. In the first reaction, Atg12 (a ubiquitin-
like protein) is conjugated to Atg5 by Atg7 and Atg10. This Atg5-Atg12 complex then 
interacts with Atg16L1 to form a complex which associates with phagophores but 
dissociates from the completed autophagosomes [95]. In the second ubiquitination-like 
reaction, LC3 is conjugated to phosphatidylethanolamine by Atg7 and Atg3 generating 
LC3-II [96]. LC3-II remains associated with the autophagosome until fusing with the 
lysosome, at which point LC3-II inside the autolysosome is degraded and LC3-II on the 
surface remains. The exact mechanism of autophagosome maturation and lysosome 
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fusion is unclear, but it is generally accepted that endosomal protein Rab7 and 
lysosomal LAMP-2 are required [97, 98]. Recent studies have also discovered other 
necessary components for fusion, including rubicon and syntaxin-5 SNARE complex [99, 
100]. Therefore, autophagosome formation and maturation is a complex process with 
many individual parts, making it prime for regulation and manipulation. 
 
1.14 Signaling inputs to autophagy 
 
Autophagy is regulated by a number of different signaling events. One of the 
primary regulators of autophagy is mTOR. When mTOR is activated, it phosphorylates 
Ulk1 preventing binding to Atg13 and FIP200 and so blocking initiation of phagophore 
generation [101] (Figure 1-4). mTOR also phosphorylates TFEB which causes TFEB to be 
retained in the cytoplasm. TFEB is a transcription factor that normally drives 
transcriptional expression of genes necessary for all stages of autophagy, but must be in 
the nucleus to do so [102]. mTOR is such a potent regulator of autophagy that inhibition 
of mTOR, such as with rapamycin, is a standard method of inducing autophagy [103]. 
JUN N-terminal kinase 1 (JNK1) also regulates autophagy by phosphorylating Bcl-2. 
When Bcl-2 is phosphorylated it dissociates from Beclin-1, freeing Beclin-1 to initiate 
phagophore generation [104]. Another protein recently discovered to regulate 
autophagy is RalB. RalB, but not RalA, directly binds to Exo84 which induces the 
assembly of Ulk1 and Vps34 complexes on the exocyst, facilitating the initiation of 
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autophagy [105]. All of these signaling pathways represent ways the cell regulates 
autophagy and possible means to manipulate normal autophagy function. 
  
24 
 
 
Figure 1-4. A number of protein complexes regulate autophagosome formation 
 
The Ulk and Vps34 complexes initiate autophagosome assembly via membrane 
nucleation. The elongation of the membrane is then facilitated by the Atg5-Atg12-
Atg16L1 complex and the lipidation of LC3-I into LC3-II. LC3-II remains bound to the 
autophagosome after maturation and is a common autophagy marker. Signaling inputs 
to autophagosome assembly include mTOR, Bcl2, and RalB. mTOR inhibits formation of 
the Ulk1 complex, Bcl2 inhibits Beclin1 and formation of the Vps34 complex, and RalB 
facilitates exocyst assembly which drives Vps35 complex assembly. 
 
 
Image reproduced from: Mizushima and Komatsu [106] 
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1.15 Autophagy and cancer  
 
 The relationship between cancer and autophagy is complex. Autophagy can both 
suppress tumor initiation and help tumor cells endure metabolic stress [107, 108]. 
Deletion of Beclin1 has been shown to increase spontaneous malignancies in mice and is 
associated with increased susceptibility to breast cancer, demonstrating that autophagy 
inhibits tumorigenesis [109, 110]. Oncogenic KRas signaling, on the other hand, can both 
suppresses autophagy through PI3K/Akt/mTOR signaling, and potentially activate 
autophagy through Raf/Erk and RalB signaling [111]. Studies supporting the requirement 
of autophagy in tumors have shown that autophagy is essential for KRas-induced 
transformation and that silencing of Beclin1 reduces KRas driven clonogenic survival 
[112, 113]. One proposed reason for the discrepancy of KRas signaling inhibiting 
autophagy and KRas-driven tumors requiring autophagy is that mutant KRas alters 
metabolism in such a way to require autophagy, possibly by mitophagy (autophagy-
mediated degradation of the mitochondria) to overcome glucose deficiency [114]. This 
hypothesis is supported by the fact that increased expression of autophagy proteins 
correlates with poor clinical outcome in patients with PDAC [115]. The dependency of 
some tumors on autophagy has created interest in the potential for anti-autophagy 
therapeutics for cancers. Chloroquine (CQ), a compound that inhibits the acidification of 
the autophagosome, in combination with the Src family kinase inhibitor saracatinib, was 
shown to decrease prostate tumor growth in mice by 64% compared to 26% with 
saracatinib alone [116]. On the basis of such clinical studies, several Phase I/II trials are 
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currently being performed with hydroxychloroquine (a modified, more soluble, version 
of CQ) in a variety of tumor types, including pancreatic cancer [108]. 3-methyladenine 
(3-MA) inhibits autophagosome generation by blocking the production of PI3P [117]. In 
mice, combination of 3-MA and the chemotherapeutic 5-fluorouracil inhibited xenograft 
tumor growth more significantly than 5-fluorouracil alone [118]. In spite of the complex 
relationship between cancer and autophagy, autophagy inhibitors have emerged as 
promising anti-cancer therapeutics. 
 
1.16 4-Phenylbutric acid 
 
4-Phenylbutric acid (4-PBA) is a low molecular weight fatty acid with a variety of 
potential clinical applications. Primarily, 4-PBA is approved for clinical use in patients 
with urea cycle disorders due to its activity as an ammonia scavenger [119]. Also, 4-PBA 
has the ability to induce β-globin expression in precursor red blood cells and is used to 
treat sickle cell disease and thalassemia [120]. Other 4-PBA applications include 
neuroprotective effects in mouse models of Alzheimer’s and Parkinson’s disease and 
restoration of glucose homeostasis in mouse models of type II diabetes [121-123].  
The variety of physiological effects of 4-PBA can be accredited to two reported 
functions, as an HDAC inhibitor and a chemical chaperone. The HDAC inhibitor activity of 
4-PBA induces differentiation in tumor cells and has led to 4-PBA being used as basis in 
HDAC inhibitor design and synthesis [124]. Because of its potential anti-tumor activity, 
4-PBA has also been tested in Phase I trials in patients with prostate cancer [125]. The 
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other reported function of 4-PBA is as a chemical chaperone serving to stabilize the 
folded conformation of a protein [126]. The understanding that 4-PBA is a chemical 
chaperone partly comes from a study in which 4-PBA stabilized a mutated protein 
(ΔF508-CFTR) commonly misfolded in cystic fibrosis [127]. Later studies also found that 
4-PBA treatment decreased expression of ER stress markers in mice [123]. ER stress is 
caused by the accumulation of unfolded protein in the ER, thus can be reversed by 
inducing protein folding [128]. The suggested dual activity of 4-PBA gives it much 
potential as a therapeutic agent, but may cause different effects in various cell types 
and conditions. 
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CHAPTER 2. MATERIALS AND METHODS 
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2.1 General cell culture and drug treatments 
 
 ELT3 cells were a gift from Dr. Cheryl Walker (MD Anderson) and were 
maintained in DF-8 media as described by Walker and Ginsler [129]. MIA-PACA-2 and 
PANC1 cells were obtained from Dr. Murray Korc (Indiana University School of 
Medicine). MIA-PACA-2 and HeLa cells were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) with 10% fetal bovine serum (FBS) (Atlanta Biologicals) and a 
penicillin-streptomycin antibiotic mixture. PANC1 cells were maintained in DMEM/5% 
FBS/penicillin-streptomycin. To facilitate passage of each cell line, the cells were washed 
once with Phosphate Buffered Saline (PBS) and then treated with trypsin EDTA for 5 
minutes. The cells were then resuspended in their respective media to inactivate the 
trypsin. Cells were frozen slowly in 10% DMSO/20% FBS/DMEM. To starve cells of 
glucose, media was changed to glucose-free DMEM (Gibco) or glucose/L-
glutamine/phenol red free DMEM (Gibco) supplemented with fresh L-glutamine. 
In experiments with 4-PBA (Santa Cruz), ELT3 cells were treated with 5 mM 4-
PBA for 24 hrs before addition of 20 nM bortezomib (LC laboratories) for an additional 6 
hrs. Prereatments with trichostatin A (TSA) (Cell Signaling) were performed in the same 
way as 4-PBA, except TSA was added at 1 μM. Tubastatin (Cayman) was added to ELT3 
cells for 1 hr at 10 μM prior to bortezomib treatment. ELT3 cells were treated with 5 
mM 3-MA (Acros Organics) for 24 hrs prior to bortezomib treatment. For experiments 
using chloroquine (CQ) (Sigma Aldrich), 10 μg/ml CQ was added to PANC1 and MIA-
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PACA-2 cells at the same time as the change to glucose free media (24 hrs prior to 
harvest).  
 
2.2 Lentiviral production 
 
 To generate lentivirus, 3 million HEK 293T cells were plated in a 10 cm plate in 
DMEM/10% FBS/penicillin-streptomycin. The next day, 20 μg of the appropriate 
lentiviral vector was transfected into the 293T cells using polyethylenimine (PEI) (Sigma 
Aldrich). For each transfection, 45 μl of 2 mg/ml PEI working solution was added to 1.95 
ml Optimem (Gibco). 6 μg of VSV-G Lenti, 5 μg of pRSV-REV, and 10 μg of pMDLg/pRRe 
(lentiviral packaging vectors) were combined with 20 μg of a lentiviral vector in a total of 
1 ml Optimem. The PEI solution was then added dropwise to the DNA solution, while 
vortexing the DNA solution. Five minutes later, the solution was added dropwise to the 
plate of 293T cells. The following day, the media was changed to fresh growth media 
and then 24 hours later, the media was removed from the plate, passed through a 0.45 
μm filter, and either immediately used or snap frozen in liquid nitrogen.  
 
2.3 Western blotting and antibodies 
 
 For experiments not comparing the detergent-soluble and -insoluble fractions, 
whole cell lysates were obtained using RIPA buffer solution, composed of 50 nM Tris 
(pH=7.4), 150 nM NaCl, 2 mM EDTA, 1% Triton X-100, and 1% SDS supplemented with 
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the protease inhibitors aprotinin and PMSF. Cells were washed in cold PBA, treated with 
RIPA buffer solution, scraped off the plate, collected in  microcentrifuge at 10,000 rpm 
for 10 min at 4°C. The supernatant was transferred to a new tube and, if not 
immediately used, snapped frozen with liquid nitrogen. Lysates were normalized to 
protein concentration using a Bradford assay (Bio-Rad) and protein sample solution was 
added. To analyze RalB and Rgl2, samples were separated by electrophoresis in 10% SDS 
gels at 120V for about 1 hr. To measure acetylated tubulin and total tubulin, samples 
were subject to electrophoresis in 12% SDS gels for about 1.5 hrs. To measure the levels 
of cleaved caspase 3, lamin A/C, LC3, and beta-actin, samples were analyzed using 15% 
SDS gels for about 2 hrs. Separated proteins were transferred from gels to PVDF-FL 
membranes (Millipore) at 20V overnight. Membranes were then blocked for one hour in 
a 5% non-fat dry milk in PBS solution supplemented with 0.02% sodium azide. 
Membranes were probed with primary and secondary antibodies for one hour each. 
Between blocking and antibody incubations, membranes were washed in Tris-Buffered 
Saline solution with 0.1% Tween 20 (TBS-T). Antibodies specific to cleaved caspase 3 
(#9661), total tubulin (#2125), acetylated tubulin (#5335), lamin A/C (#4777), and LC3 
(#3868) were obtained from Cell Signaling Technologies. Antibodies specific to beta-
actin (sc-47778) and ubiquitin (sc-8017) were obtained from Santa Cruz Biotechnology. 
Antibodies specific to Rgl2 (H00005863-M02) and RalB (04-037) were obtained from 
Abnova and Millipore, respectively. Dilutions of antibodies are indicated in Table 1. 
Western blots were visualized by using X-ray film and ECL Western Blotting or 
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SuperSignal West Femto Maximum Sensitivity substrates (Thermo Scientific). The films 
were then scanned and quantitated by using ImageJ software.  
 
Table 1. Antibody dilutions 
 
Antibody Dilution 
Acetylated-tubulin 1:1000 
Cleaved caspase 3 1:1000 
Lamin A/C 1:1000 
LC3 1:1000 
Mouse-HRP 1:30,000 
Mouse-Texas-Red 1:1000 
Rabbit-HRP 1:30,000 
RalB 1:1000 
Rgl2 1:2500 
Tubulin 1:1000 
Ubiquitin 
1:200 (Western blot), 1:100 
(Immunofluorescence) 
Β-actin 1:5000 
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2.4 Immunofluorescence microscopy 
 
 To image cells using immunofluorescence, 50,000 ELT3 cells were plated on glass 
coverslips in 35 mm dishes. The next day, cells were serum starved and treated with 5 
mM 4-PBA or vehicle. 24 hrs later, cells were treated with 20 nM bortezomib or control 
for 8 hrs. Coverslips were then washed three times in cold PBS and incubated in cold 
methanol for 10 min. Coverslips were again washed three times in cold PBS and stored 
overnight in 20% in PBS at 4°C. The next day, coverslips were washed three times again 
in cold PBA and then incubated in 1:100 anti-ubiquitin antibody for one hour. After 
three more washes in cold PBS, the coverslips were incubated in 1:1000 anti-mouse-
Texas-Red (Invitrogen). The coverslips were washed three times again in cold PBS and 
mounted to a microscope slide using VECTASHIELD Hard Set Mounting Medium with 
DAPI (Vector Laboratories). The slides were imaged on a Zeiss 468 AxioObserverZ1 
microscope.  
 
2.5 Soluble/insoluble fractionation 
 
 Insoluble and soluble fractions were collected  to determine the levels of 
aggregated ubiquitinated protein. To obtain these fractions, cells were lysed in RIPA 
buffer solution as described above. After the supernatant (soluble fraction) was 
collected, however, the pellet was resuspended in 8 M Urea/5% SDS solution and boiled 
for 10 min (insoluble fraction). The insoluble fraction samples were normalized to the 
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protein levels of the paired soluble fraction levels measured with a Bradford assay (Bio-
Rad). The samples were then analyzed via Western blotting as described above. 
 
2.6 Live imaging 
 
 In order to image fluorescent GFP-RFP-LC3 and GFP-RFP-p62, MIA-PACA-2 and 
PANC1 cells were plated in 35 mm MakTek dishes with glass bottoms. To each plate, 100 
μl of the appropriate leniviral media and 3 μl 4mg/ml polybrene was added. The next 
day, media was changed and puromycin was added at 1-2 μg/ml. After two days of 
puromycin selection, media was changed to DMEM or glucose-free DMEM. Three hours 
later, the plates were either imaged on a Zeiss 468 AxioObserverZ1 widefield 
microscope or a Nikon TE-2000U inverted confocal microscope. 
 
2.7 Colony formation assay 
 
 To measure anchorage-dependent colony formation, 500 PANC1 or MIA-PACA-2 
cells were plates in 60 mm dishes with 100 μl of the appropriate lentiviral media and 6 
μl polybrene. The next day, the media was changed and puromycin was added. The cells 
were grown and puromycin selected for 8 days, changing the media every other day. On 
the eighth day, the cells were washed in PBS and fixed to the dish for 10 min in 10% 
methanol/10% acetic acid. After washing again, the dishes were stained with 0.5% 
crystal violet (Sigma Aldrich)/10% methanol/10% acetic acid. After staining, the dished 
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were rinsed in water and dried overnight on paper towel. The number of colonies was 
then counted by eye. 
 
2.8 Trypan blue assay 
 
 To measure cell death by trypan blue staining, 100,000 MIA-PACA-2 cells were 
plated in 35 mm dishes with 500 μl of the appropriate lentiviral media and 3 μl 
polybrene. The next day, the media was changed and puromycin was added. After two 
days puromycin selection, the media was changed to DMEM or glucose-free DMEM. 
Thirteen hours later, the media from each was collected, each dish was washed with 
1ml PBS, and the wash was collected. The cells were then released from the dish with 
500 μl of trypsin EDTA and pooled with the matched media and wash. Each sample was 
then centrifuged at 800 rpm at 4°C for 5 min. The supernatant was next aspirated off 
and the pellet of cells was resuspended in 200 μl cold PBS. After vortexing, 10 μl of the 
sample was combined with 10 ul PBS:0.4% Trypan blue (Sigma Aldrich). This mixture was 
then put on a hemocytometer (Reichert) and images were taken with a light 
microscope. The number of living and dead cells was then counted from these images in 
ImageJ.  
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2.9 Statistical Analysis 
 
 Western blot quantitation was performed in ImageJ and exported to Microsoft 
Excel. The background of each blot was subtracted from each sample measurement and 
each sample was normalized to its corresponding beta-actin measurement (acetylated 
tubulin was normalized to total tubulin). The Western blot data was then normalized to 
the control sample of each experiment.  
  To quantitate GFP-RFP-p62 signal in PANC1 cells, images were first exported to 
Adobe Photoshop Elements. Individual cells were outlined and the red signal was set at 
a 50% threshold. Any cell with remaining red signal was considered positive. To 
quantitate GFP-RFP-LC3 signal in MIA-PACA-2 cells, images were first exported to 
ImageJ. Individual cells were outlined and the red signal was set to an automatic 
threshold using the Image>Adjust>Auto Threshold>MaxEntropy function. The number 
of red vesicles was then determined with the Analyze>Analyze Particles function. Due to 
variable expression per cell, individual thresholds for green signal were set for each cell. 
To threshold the green signal, the mean intensity of the cytosol was first measured. The 
threshold was then set to the mean intensity of the cytosol multiplied by two using the 
Image>Adjust>Threshold function (the value of the multiplier was determined 
empirically). The number of green vesicles was then determined using the 
Analyze>Analyze Particles function. The reported “Percent of Mature Autophagosomes” 
is the difference of the number of red vesicles and green vesicles divided by the number 
of red vesicles. 
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Bar graphs represent data from 2 to 4 experiments with error bars representing 
the standard deviation from the mean for sets of experiments of 3 or more. Reported p-
values were calculated using the Student’s T-test function in Microsoft Excel (only for 
sets of 3 or more experiments). 
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CHAPTER 3. TREATMENT WITH 4-PBA INHIBITS CELL SURVIVAL AND STRESS 
INDUCED AGGRESOME FORMATION IN ELT3 CELLS 
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3.1 Introduction 
 
 Newly synthesized proteins must first be properly folded before they can be 
functional. Misfolded proteins can aggregate and excessive protein aggregation is toxic 
to the cell [83]. The cell has three mechanisms to deal with misfolded proteins: folding 
the protein with a chaperone protein, degrading the misfolded protein via the 
proteasome, or sequestering the protein aggregates at an aggresome to be degraded 
via autophagy [84]. Cells with excessive mTOR activity have increased protein synthesis 
and therefore a greater requirement for protein folding [130]. Therefore, these cells are 
more vulnerable to protein clearance inhibition. We hypothesized that inhibiting both 
aggresome formation and proteasomes will induce death of TSC2 null cells. 
 HDAC6 is required to recruit protein aggregates to the aggresome [86]. 
Therefore, inhibition of HDAC6 should prevent aggresome formation and cause an 
accumulation of toxic protein aggregates in the cytosol. The small compound 4-PBA has 
been reported to be both a chemical chaperone and to inhibit HDAC activity. We 
hypothesized that inhibition of HDAC6 by 4-PBA would overcome its protein folding 
activity and induces aggregate-induced toxicity. We hoped to exacerbate this effect by 
blocking protein clearance through the proteasome with the proteasome inhibitor, 
bortezomib.  
 We tested the combined effect of 4-PBA and bortezomib in ELT3 cells, a rat TSC2 
null model, and found that the combination induces greater cell death compared to 
either compound alone. 4-PBA also decreases the accumulation of protein aggregates 
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induced by bortezomib treatment. In order to link this reduction in aggregates with 
HDAC inhibition, we repeated the experiment with the pan-HDAC inhibitor trichostatin 
A (TSA) and the HDAC6-specific inhibitor tubastatin. Both TSA and tubastatin also 
decrease the aggregate accumulation induced by bortezomib in ELT3 cells. 4-PBA was 
not, however, able to increase tubulin acetylation, a target of HDAC6. Because the 
aggresome is also degraded through autophagy, we hypothesized that 4-PBA could 
alternatively be inducing autophagy. Experiments with the autophagy inhibitor 3-
methyladenine (3-MA), however, did not restore aggregate accumulation. Therefore, 4-
PBA induces cell death and decreases aggregate accumulation, but these phenomena 
appear to be independent of HDAC6 activity or autophagy.      
 
3.2 Results 
 
 3.2.1 Treatment with 4-PBA increases cell death 
 
Reports in the literature suggest that 4-PBA can be protective against cellular 
stress, but this work was done in mice with genetically induced ER stress [123]. 
Therefore, we wanted to first test how 4-PBA affects cell survival during proteasome 
inhibition in our TSC model, ELT3 cells. ELT3 cells were pretreated with 5mM 4-PBA or 
vehicle for 24 hrs and then treated with 20nM bortezomib for 0, 12, 15, or 18 hrs. 
Cleaved caspase 3 was then measured as a marker of apoptosis. Cells pretreated with 4-
PBA exhibited increased levels of apoptosis after 12, 15, and 18 hrs of proteasome 
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inhibition (Figure 3-1). Contrary to previous findings, these results suggest 4-PBA 
increases the cellular stress induced by proteasome inhibition in this cell type [123].  
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Figure 3-1. Treatment with 4-PBA increases ELT3 cell death 
 
A. ELT3 cells were treated with 5 mM 4-PBA or vehicle for 24 hrs and then with 
bortezomib or vehicle for 0, 12, 15, or 18 hrs. Cleaved caspase 3 and beta-actin levels 
were then determined via immunoblot analysis. Blot is representative of three 
experiments. 
 
B. Quantification of A. All conditions normalized to beta-actin levels. Error bars 
represent standard deviation of the mean and p-values determined with a Student’s T-
Test. 
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3.2.2 Treatment with 4-PBA decreases protein aggregation 
 
The aggresome is typically defined as a perinuclear accumulation of 
ubiquitinated and aggregated proteins [83]. Therefore, fluorescent imaging of the 
localization of ubiquitinated proteins and biochemically measuring total ubiquitinated 
protein aggregates are two of the best ways to measure the aggresome. Because of its 
HDAC inhibiting activity, we predicted that 4-PBA inhibits HDAC6 to inhibit aggresome 
formation. To test this, we pretreated ELT3 cells with 5 mM 4-PBA or vehicle for 25 hrs 
and then with bortezomib for a further 8 hrs (still in presence of 4-PBA). Bortezomib was 
used to prevent misfolded protein degradation through the proteasome and 
consequently enhance aggresome formation.  Immunofluorescence microscopy analysis 
was then performed on these cells with an anti-ubiquitin probe (conjugated to Texas 
Red) and a nuclear marker (DAPI). Bortezomib treatment induced perinuclear 
accumulation of ubiquitin puncta, but pretreatment with 4-PBA decreased this effect 
(Figure 3-2a). To measure protein aggregation in an additional way, ELT3 cells were 
pretreated with 5 mM 4-PBA or vehicle for 24 hrs followed by the addition of 20 nM 
bortezomib to the medium for 0, 2, 4, or 6 hrs. The cells were then lysed in RIPA buffer 
solution and separated into soluble and insoluble fractions by centrifugation. Protein 
aggregates are not soluble in RIPA but the pellet could be subsequently solubilized in 8 
M Urea/5% SDS and separated by SDS-PAGE for detection of ubiquitinated proteins by 
Western blot. Bortezomib treatment induced an accumulation of ubiquitinated protein 
in the insoluble fraction. While not statistically significant, there was a consistent trend 
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of 4-PBA reducing this accumulation in each of three experiments(Figure 3.2b). Both the 
immunofluorescence and biochemical experimental results suggest that 4-PBA 
decreases aggresome formation induced by proteasome inhibition.  
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Figure 3-2. Treatment with 4-PBA decreases ubiquitinated protein aggregation 
 
A. ELT3 cells were treated with 5 mM 4-PBA or vehicle for 24 hrs and then with 
bortezomib or vehicle for 8 hrs. Immufluorescent analysis was then performed with an 
anti-ubiquitin-Texas-Red antibody and a DAPI stain. Images are representative of three 
experiments. 
 
B. ELT3 cells were treated with 5 mM 4-PBA or vehicle for 24 hrs and then with 
bortezomib or vehicle for 0, 2, 4, or 6 hrs. The lysates were then separated into soluble 
and insoluble fractions. Soluble ubiquitin, soluble beta-actin, and insoluble ubiquitin 
levels were then determined via immunoblot analysis. Blot is representative of three 
experiments. 
 
C. Quantification of B. Error bars represent standard deviation of the mean and p-values 
determined with a Student’s T-Test. 
  
47 
 
3.2.3 Treatment with HDAC inhibitors decreases protein aggregation 
 
We next sought to determine how 4-PBA reduces aggresome accumulation. 4-
PBA has been used as a lead compound in the synthesis of HDAC inhibitors and exhibits 
HDAC-attenuating ability [124]. We hypothesized that 4-PBA inhibits HDAC6, which is 
required to recruit protein aggregates to the aggresome [86]. Therefore, we attempted 
to reproduce this effect with other HDAC inhibitors, TSA and tubastatin. ELT3 cells were 
pretreated with 5 mM 4-PBA or 1 μM TSA for 24 hrs or with 10 μM tubastatin for 1 hr, 
prior to a 6 hr treatment with 20 nM bortezomib. Time course experiments were 
performed to determine the ideal treatment time for each HDAC inhibitor, tubastatin 
only required 1 hr treatment while TSA and 4-PBA required 24 hrs (data not shown). 
Ubiquitin levels were then analyzed in both the RIPA buffer soluble and insoluble 
fractions. As before, treatment with bortezomib induced ubiquitinated protein 
aggregates. In a similar manner to 4-PBA, TSA and tubastatin decreased this 
accumulation (Figure 3-3). These results supported the notion that 4-PBA reduces 
protein aggregation via HDAC inhibition. 
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Figure 3-3. Treatment with HDAC inhibitors decreases ubiquitinated protein 
aggregation 
 
A. ELT3 cells were treated with 5 mM 4-PBA, 1 μM TSA, or vehicle for 24 hrs or 10 μM 
tubastatin for 1 hr. The cells were then treated with bortezomib or vehicle for 6 hrs. The 
lysates were then separated into soluble and insoluble fractions. Soluble ubiquitin, 
soluble beta-actin, and insoluble ubiquitin levels were then determined via immunoblot 
analysis. Blot is representative of three experiments. 
 
B. Quantification of A. Error bars represent standard deviation of the mean and p-values 
determined with a Student’s T-Test. 
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3.2.4 4-PBA treatment does not increase tubulin acetylation 
 
Because of its role in aggresome formation, we next wanted to determine if 4-
PBA inhibits HDAC6 activity. One target of HDAC6 is tubulin; therefore, HDAC6 inhibition 
should increase tubulin acetylation. To test this, ELT3 cells were pretreated with 5 mM 
4-PBA or 1 μM TSA for 24 hrs or 10 μM tubastatin for 1 hr, prior to a 6 hr treatment with 
20 nM bortezomib. The pretreatment times for the HDAC inhibitors were used in order 
to stay consistent with the data in Figure 3.2.3. Lysates were then probed for total 
tubulin and acetylated tubulin using a specific anti-acetyl group antibody. Tubastatin, an 
HDAC6 specific inhibitor, increased tubulin acetylation but neither 4-PBA nor TSA, a pan-
HDAC inhibitor, affected acetylation levels (Figure 3-4). This result suggested that 
HDAC6 inhibition is not the mechanism by which these compounds decrease protein 
aggregates. 
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Figure 3-4. 4-PBA treatment does not increase tubulin acetylation 
 
A. ELT3 cells were treated with 5 mM 4-PBA, 1 μM TSA, or vehicle for 24 hrs or 10 μM 
tubastatin for 1 hr. The cells were then treated with bortezomib or vehicle for 6 hrs. 
Total tubulin, acetylated tubulin, and beta-actin levels were then determined via 
immunoblot analysis. Blot is representative of three experiments. 
 
B. Quantification of A. All conditions normalized to total tubulin levels. Error bars 
represent standard deviation of the mean and p-values determined with a Student’s T-
Test. 
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3.2.5 Autophagy inhibition does not restore protein aggregation decreased by 4-
PBA 
 
The reduction in aggresomes caused by 4-PBA treatment could either be caused 
by an inhibition in aggresome formation or an increase in aggresome clearance. The 
method of clearance for the aggresome is thought to be autophagy. Therefore, 4-PBA 
may be increasing the rate of autophagy. To test if this is the case, the autophagy 
inhibitor 3-methyladenine (3-MA) was used. ELT3 cells were pretreated with 5 mM 4-
PBA or vehicle and 5 mM 3-MA or vehicle for 24 hrs, and then treated with 20 nM 
bortezomib for 6 hrs. Ubiquitin levels were then analyzed in both the RIPA buffer 
soluble and insoluble fractions. LC3 levels were also measured in the soluble control and 
3-MA treated samples to ensure autophagy inhibition. 3-MA treatment successfully 
inhibited LC3-II clearance in the ELT3 cells (Figure 3-5). As before, 4-PBA decreased the 
bortezomib-induced accumulation of aggregated proteins. Cotreating with 3-MA, 
however, did not prevent this 4-PBA-induced aggregate reduction (Figure 3-5). 
Therefore, the reduction in aggresomes caused by 4-PBA is not dependent on 
autophagy.  
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Figure 3-5. 3-MA treatment does not restore protein aggregation decreased by 4-PBA  
 
A. ELT3 cells were pretreated with 5 mM 4-PBA or vehicle and 5 mM 3-MA or vehicle for 
24 hrs and then with bortezomib or vehicle for 6 hrs. The lysates were then separated 
into soluble and insoluble fractions. Soluble ubiquitin, soluble beta-actin, and insoluble 
ubiquitin levels were then determined via immunoblot analysis. Blot is representative of 
two experiments. LC3 levels were determined separately as a control in the control and 
3-MA treated samples.  
 
B. Quantification of A. Statistics not performed due to only two experiments performed. 
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3.3 Discussion 
 
 3.3.1 4-PBA treatment does not protect against cell death 
 
 It was previously reported in the literature that 4-PBA is protective against 
cellular stress. A large amount of unfolded protein will increase stress, and the ability of 
4-PBA to reduce stress was accredited to its activity as a chemical chaperone [123]. Our 
findings suggest, however, that 4-PBA treatment increases cell death in ELT3 cells 
(Figure 3-1). Our hypothesis was that the HDAC6 inhibitory activity of 4-PBA was 
overcoming its ability to fold protein and actually inhibiting aggresome formation. This 
mechanism of cell death, by inhibiting aggresome formation, has also been reported in 
the literature. In a study by Zhou et al., proteasome inhibition sensitized TSC2 null cells 
to cell death due to aggregate accumulation [131]. Our findings, however, demonstrate 
a novel chemical mechanism of inducing this effect. Other work has also shown that 
HDAC inhibition can abrogate aggresome formation. Inhibiting both HDACs and the 
proteasome increased cell death in multiple myeloma cells [132]. We also found that 4-
PBA treatment reduces bortezomib-induced aggresome accumulation (Figure 3-2). 
These findings of the increased cell death and decreased aggresome accumulation 
caused by 4-PBA treatment support our hypothesis.  
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3.3.2 The inhibition of aggresome formation by 4-PBA treatment does not 
correlate with HDAC6 inhibition 
 
 To test if the ability of 4-PBA to reduce aggresomes was due to its HDAC 
inhibitory activity, we repeated the experiment with other HDAC inhibitors. The pan-
HDAC inhibitor, TSA, and the HDAC6-specific inhibitor, tubastatin, both reduced 
bortezomib-induced aggresomes in ELT3 cells (Figure 3-3). These results confirm 
previous findings and correlate with the effects of 4-PBA treatment [132]. To connect 
the reduction in aggresomes with HDAC6 inhibition we measured the level of tubulin 
acetylation after 4-PBA, TSA, and tubastatin treatment. Because tubulin is a target of 
HDAC6, HDAC6 inhibition will cause an increase in tubulin acetylation. Tubastatin 
treatment increased tubulin acetylation, but 4-PBA and TSA did not (Figure 3-4). 
Because tubastatin is specific to HDAC6, tubastatin is expected to have a more intense 
effect on tubulin acetylation. 4-PBA and TSA, however, did not even have a measurable 
effect. One explanation for this could be treatment duration of the HDAC inhibitors. 4-
PBA and TSA required 24 hr pretreatment to reduce aggresome accumulation, but 
tubastatin only required one hour. Long exposure to HDAC inhibitors has an effect on a 
number of cellular pathways, including gene expression and genomic stability [133]. 
Therefore, treatment with 4-PBA may indirectly alter another cellular mechanism 
resulting in a reduction of aggresomes. We hypothesized next that instead of 4-PBA 
inhibiting aggresome formation, it is actually increasing aggresomal degradation. The 
pathway for aggresomal degradation is thought to be autophagy [84]. Thus, we 
57 
 
attempted to use 3-MA to inhibit autophagy and restore aggresome levels. Cotreating 
cells with 4-PBA and 3-MA did not, however, restore bortezomib-induced aggregate 
levels (Figure 3-5).  Therefore, 4-PBA-mediated reduction in aggregate levels is 
independent of HDAC6 and autophagy. The fact that TSA and tubastatin also reduced 
aggregate levels, however, suggests that this effect is due to HDAC inhibition. One 
possible mechanism could be changes in gene expression, a typical result of HDAC 
inhibition since chromatin/histones is their major target [133]. A global reduction in 
gene expression would decrease unfolded protein levels and stress, especially in TSC2 
cells. Our findings show that 4-PBA increases ELT3 cell death and decreases aggresome 
levels, but the relationship between these phenomena remains unclear.  
 
3.4 Future directions 
 
 A number of further experiments could be done to determine the exact 
mechanism in which 4-PBA and the other HDAC inhibitors reduce protein aggregates. 
Because of the long treatment time required for 4-PBA and TSA to have an effect, we 
hypothesize that these compounds may have an effect on global gene expression. TSC2 
null cells (such as ELT3 cells) have increased gene expression due to constitutive mTOR 
activity. HDAC inhibition has been to shown to reduce gene expression [133]. Therefore, 
the reduction in aggresomes caused by 4-PBA treatment may just be due to reduced 
gene expression and less requirement for protein folding. We could then determine if 
actinomycin (a transcription inhibitor) or cycloheximide (a translation inhibitor) inhibit 
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bortezomib-dependent protein aggregation. A reduction in aggresomes caused by these 
compounds would then correlate with our 4-PBA data. Another way to test this 
hypothesis would be to directly measure how 4-PBA affects gene expression. A radio-
labeled amino acid chase experiment with or without 4-PBA would demonstrate how 4-
PBA alters protein synthesis. This experiment would be done with a variety of 4-PBA 
treatment times to determine if any effect is time-dependent. A reduction in global 
protein synthesis with 4-PBA treatment (specifically at longer treatment times) would 
suggest there is a correlation between protein synthesis and aggresome formation. To 
determine if 4-PBA, TSA, and tubastatin increase protein folding, a mutated cystic 
fibrosis transmembrane conductance regulator construct (ΔF508-CFTR) could be used. 
ΔF508-CFTR will only fold, and thus be detected via Western blotting, under conditions 
that promote protein folding (such as in the presence of a chaperone) [134]. ΔF508-
CFTR could then be expressed in cells and then we could determine if 4-PBA, TSA, or 
tubastatin is able to induce folding. There is evidence that 4-PBA does restore ΔF508-
CFTR folding, but it is unclear if TSA or tubastatin also do [127]. If all three HDAC 
inhibitors do restore ΔF508-CFTR folding, then the reduction in aggresomes may be due 
to a reduction in misfolded protein. Also, our hypothesis was based on the cells being 
TSC2 null, thus having higher protein synthesis and stress. Further experiments with 
cells with wild type TSC2 could determine if 4-PBA also induces cell death during 
proteasome inhibition. These experiments would help explain how 4-PBA and the other 
HDAC inhibitors reduce aggregated proteins. 
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CHAPTER 4. RGL2 LOSS INHIBITS CELL SURVIVAL BUT NOT AUTOPHAGY IN MIA-PACA-2 
PANCREATIC CANCER CELLS 
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4.1 Introduction 
 
 Over 90% of PDAC tumors have activating mutations in KRas, which leads to 
constitutive KRas signaling [60].  This then causes increased activity of such downstream 
effectors as PI3K, Raf, and the RalGDS proteins. Because of their increased activity in 
pancreatic cancer, much research has been done attempting to therapeutically target 
KRas and its effectors. However, little success has been achieved in this regard [135]. 
Less research, though, has targeted the Ral pathway relative to the other KRas effectors. 
Recent work has shown that Rgl2 is overexpressed in PDAC and loss of Rgl2 inhibits 
PDAC cell survivals [50]. Because of these results, we looked into what are the 
underlying mechanisms by which Rgl2 can regulate cell survival. The abovementioned 
study showed that mutationally activated RalA only partially restored survival reduced 
by loss of Rgl2 and showed that loss of Rgl2 preferentially inhibits RalB activation over 
RalA [50]. These two findings lead us to hypothesize that Rgl2 stimulates survival via 
some RalB-dependent mechanism(s). A separate study showed that RalB facilitates the 
binding of Ulk1 and Vps34 complexes onto the exocyst, initiating autophagosome 
formation [105]. Although autophagy can be a possible death pathway, there is also 
much evidence that suggests that autophagy can promote survival in tumor cells, 
especially in low nutrient environments (such as a PDAC tumor) [136]. Therefore we 
hypothesized that Rgl2 promotes PDAC cell survival by facilitating autophagy and 
subsequent reclamation of nutrients. 
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 We first wanted to determine if loss of Rgl2, and not another RalGEF, decreased 
autophagy in PANC1, a PDAC cell line. We focused on the two RalGEFs that have been 
shown to have highest expression in PDAC cells, RalGDS and Rgl2 [50]. Our initial 
experiments with a fluorescent LC3 construct showed that loss of Rgl2 and not RalGDS 
inhibited autophagosome maturation. To confirm that loss of Rgl2 inhibits PDAC 
survival, we again used shRNA to decrease Rgl2 levels in PANC1 and MIA-PACA-2 cells, 
another KRas mutant PDAC cell line. Loss of Rgl2 decreased colony formation in both 
these cells and increased cell death in MIA-PACA-2 cells. We next developed a 
quantitative method of measuring p62-positive cells by counting the number of cells 
with signal above a 50% threshold. Initial quantitation methods demonstrated that loss 
of Rgl2 decreased total number of autophagosomes. This method of measuring 
autophagosomes, however, had a number of weaknesses. To address these method 
deficiencies, another quantitation method was developed to specifically count the 
number of mature and immature autophagosomes per cell. Alternatively, this more 
sophisticated method revealed that loss of Rgl2 had no effect on LC3-positive 
autophagosome number or maturation. To elaborate on the fluorescent autophagy 
data, we next measured the effects of loss of Rgl2 on endogenous LC3 levels. We first 
measured how glucose starvation changed LC3 levels in PDAC cells, using HeLa cells as a 
control cell line. Glucose starvation caused a decrease in LC3-II levels in HeLa cells, but 
increased LC3-II levels in the two PDAC cell lines. We then measured how the loss of 
Rgl2 affects LC3 loss in the PDAC cells. Surprisingly loss of Rgl2, or the positive control 
RalB, did not inhibit starvation-induced increase in the PDAC cell lines. Because LC3 
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levels are constantly in flux during autophagy, we next used the autophagy inhibitor CQ 
to measure the accumulation of LC3-II. Loss of Rgl2 and RalB, however, did not inhibit 
the accumulation of LC3-II. The imaging data together with the endogenous LC3 data 
revealed that while loss of Rgl2 inhibits survival, it does not significantly inhibit 
autophagy.  
 
4.2 Results 
 
4.2.1 Rgl2 but not RalGDS loss inhibits autophagosome maturation in PANC1 
cells  
  
 RalGDS and Rgl2 are both highly expressed in PDAC cell lines [50]. Therefore, we 
first determined if loss of either RalGEF inhibited autophagosome maturation. To 
measure autophagosome maturation, we used a doubly- RFP/GFP tagged fluorescent-
LC3. Fluorescence from the RFP tag persists in the low pH environment of lysosomes but 
that of GFP is quenched. Therefore, a mature acidified autophagosome will be red while 
an immature autophagosome will appear “yellow” (fluorescing both red and green) [98]. 
PANC1 cells were infected via lentivirus with the LC3 construct and RalGDS, Rgl2, or 
control shRNA. The cells were then glucose starved for 3 hrs to induce autophagy and 
imaged live with a widefield microscope. After starvation, the cells infected with the 
RalGDS shRNA appeared to have more red vesicles than the cells infected with the 
control shRNA. Loss of Rgl2, however, caused an increase in the amount of immature 
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(yellow) autophagosomes after starvation (Figure 4-1). These results suggested that the 
loss of Rgl2, but not RalGDS, inhibits autophagosome maturation. Loss of RalGDS, 
however, was not able to be confirmed due to the lack of a commercially available 
antibody. Quantitative PCR experiments were attempted to determine efficacy of 
RalGDS shRNA, but were not successfully optimized. Further attempts to optimize were 
halted due to lack of focus on RalGDS. Also, the low resolution and high background 
signal prevented quantitation of the number of vesicles per cell, a problem addressed in 
Chapters 4.2.4 and 4.2.5. Regardless, these results encouraged further analysis of the 
relationship between Rgl2 and autophagy.  
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Figure 4-1. Rgl2 but not RalGDS loss inhibits autophagosome maturation in PANC1 
cells 
 
A. PANC1 cells were infected with control, RalGDS, or Rgl2 shRNA as well as a GFP-RFP-
LC3 construct. After three days of puromycin selection, cells were glucose starved for 
three hours and images were taken with a widefield microscope. Images are 
representative of two experiments. 
 
B. Rgl2 and beta-actin levels from the control and shRgl2 samples from A. were 
determined using immunoblot analysis. RalGDS levels were not determined due to lack 
of a commercially available antibody. Blot is representative of two experiments. 
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 4.2.2 Loss of Rgl2 inhibits anchorage-dependent colony formation in PDAC cells 
 
 We next sought to confirm that the loss of Rgl2 inhibits PDAC cell viability. 
Previous work observed that the loss of Rgl2 inhibited anchorage-independent colony 
formation [50]. We repeated this experiment, but measured anchorage-dependent 
colony formation instead. This assay is the gold standard in cancer cell biology [137] for 
identifying genes necessary for cancer cell growth and will supplement the previous 
findings. We used shRNA to decrease Rgl2 levels in PANC1 and MIA-PACA-2 cells and 
then plated the cells at very low confluency. Eight days later the number of colonies was 
measured. Loss of Rgl2 caused a loss in the number of adherent colonies in both PDAC 
cell lines (Figure 4-2). These results confirm findings from previous studies and 
demonstrate that loss of Rgl2 inhibits PDAC cell viability [50].  
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Figure 4-2. Loss of Rgl2 inhibits anchorage-dependent colony formation in PDAC cells 
 
A. A low number of PANC1 cells were infected with control or Rgl2 shRNA and were 
grown and selected with puromycin for eight days. At that point, colonies were stained 
with crystal violet and counted. The levels of Rgl2 and beta-actin were also measured 
using immunoblot analysis in samples plated in parallel. Error bars represent standard 
deviation of the mean and p-values determined with a Student’s T-Test. Data is 
exemplary of two experiments. 
 
B. The above assay was performed using MIA-PACA-2 cells. Error bars represent 
standard deviation of the mean and p-values determined with a Student’s T-Test. Data is 
exemplary of two experiments. 
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 4.2.3 Loss of Rgl2 increases cell death in MIA-PACA-2 cells 
 
 To further support the data from chapter 4.2.2 and demonstrate how Rgl2 
promotes cell viability, we next addressed the mechanism by which loss of Rgl2 affects 
PDAC cell survival. To do so, Rgl2 was knocked down using shRNA in MIA-PACA-2 cells. 
Cells were also glucose starved, to measure cell death in autophagic conditions. Cell 
death was then measured in two ways. First, the dead cells were stained with trypan 
blue and counted. Loss of Rgl2 caused a significantly higher number of dead MIA-PACA-
2 cells. Also, cleaved lamin A/C fragment levels were measured as a marker of 
apoptosis. While not significant, there was a trend in three different experiments that 
loss of Rgl2 increased lamin A/C fragment levels both with and without glucose 
starvation. Loss of Rgl2 did not, however, induce cell death in PANC1 cells (data not 
shown). These results demonstrate that loss of Rgl2 inhibits cell survival in addition to 
colony formation in MIA-PACA-2 cells.  
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Figure 4-3. Loss of Rgl2 increases MIA-PACA-2 cell death 
 
A. MIA-PACA-2 cells were infected with control or Rgl2 shRNA and conditions were 
plated in triplicate. After three days of selection, cells were glucose starved for 24 hrs. 
At that point, the media and cells were harvested and the number of dead cells was 
identified using trypan blue. The levels of Rgl2 and beta-actin were also measured using 
immunoblot analysis in samples plated in parallel. Data is representative of the 
combined data of two experiments. Error bars represent standard deviation of the mean 
and p-values determined with a Student’s T-Test. 
 
B. MIA-PACA-2 cells were infected with control or Rgl2 shRNA and selected with 
puromycin for three days. At that point, cells were glucose starved for 24 hrs and lysates 
were harvested. Lamin A/C, Rgl2, and beta-actin levels were then determined using 
immunoblot analysis. Blot is representative of three experiments. 
 
C. Quantification of B. All conditions normalized to beta-actin levels. Error bars 
represent standard deviation of the mean and p-values determined with a Student’s T-
Test. 
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4.2.4 Loss of Rgl2 decreases total p62-positive puncta in PANC1 cells during 
glucose starvation 
 
 Due to low resolution and high background, we were unable to quantitate the 
previous autophagy microscopy data (Figure 4-1). To generate quantifiable data, we 
used a p62 fluorescent construct instead of the LC3 construct. We observed that p62 
only localized to puncta when autophagy was induced, as opposed to LC3 which forms 
puncta without stimulation. This observation led us to generate a quantitation method 
with the p62 construct. PANC1 cells were infected with the doubly tagged p62 construct 
and Rgl2 or control shRNA. PANC1 cells were used to be consistent with Figure 4-1. The 
cells were then glucose starved for 3 hrs to induce autophagy and imaged live with a 
widefield microscope. The images were exported to Adobe Photoshop, individual cells 
were outlined, and the red signal was set at a threshold of 50%. Any cell still containing 
red signal after thresholding was then considered positive. Glucose starving the control 
cells caused an increase in the number of positive cells. The samples without Rgl2 did 
not exhibit this starvation-induced increase in number of positive cells, and starved 
samples without Rgl2 had significantly less positive cells than starved control cells 
(Figure 4-4). This method of quantitating autophagy supports the idea that loss of Rgl2 
inhibits autophagy. This method of quantitation, however, has a number of potential 
shortcomings. The number of puncta per cell and the maturity of the vesicle (color) are 
two pieces of information that are lost by measuring this way. Because of these flaws, 
we next sought a better method of quantitating autophagy. 
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Figure 4-4. Loss of Rgl2 decreases total p62-positive puncta in PANC1 cells during 
glucose starvation 
 
A. PANC1 cells were infected with control or Rgl2 shRNA as well as a GFP-RFP-p62 
construct. After three days of puromycin selection, cells were glucose starved for three 
hours and images were taken with a widefield microscope. Images are representative of 
four experiments. 
 
B. Quantitation of images from A. To quantitate, images were exported to Adobe 
Photoshop, individual cells were identified, and the red signal was set at a 50% 
threshold. Any cell still containing red signal after the threshold was considered positive. 
Data is representative of four experiments. Error bars represent standard deviation of 
the mean and p-values determined with a Student’s T-Test. 
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4.2.5 Loss of Rgl2 has no effect on autophagosome maturation in MIA-PACA-2 
cells 
  
 A few measures were then taken to develop a more improved method of 
quantitating autophagy. First, to improve the resolution and facilitate measuring 
individual puncta, a confocal microscope was used instead of a widefield microscope. 
Also, the doubly-tagged fluorescent LC3 construct was used instead of the p62 
construct. The LC3 construct allows for measuring changes in acidity more readily than 
the p62 construct (determined empirically and reflected in the data). Lastly, the number 
of puncta per cell was measured versus the total number of cells with thresholded 
signal. To gather images, MIA-PACA-2 cells were infected with the doubly tagged LC3 
construct and Rgl2, RalB, or control shRNA. MIA-PACA-2 cells were used for these 
imaging experiments in order to stay consistent with the survival data (Figure 4-3). The 
cells were then glucose starved for 3 hrs to induce autophagy and imaged live with a 
confocal microscope by the contributor Seth Winfree. The images were exported to 
ImageJ, cells were outlined, and red and green signals were separately thresholded. The 
number of puncta was determined automatically with the ImageJ software. Supporting 
published data, loss of RalB inhibited the starvation-induced accumulation of mature 
autophagosomes and decrease in immature autophagosomes (Figure 4-5). Nonstarved 
cells without RalB had similar levels of immature and mature autophagosomes 
compared with starved control cells. These results suggest that loss of RalB may increase 
autophagy levels even in cells not subject to starvation, an idea further pursued in 
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Chapter 4.2.8. The level of autophagosomes in all conditions was not significantly 
different in cells without Rgl2 compared to control cells. The method of quantitation 
described in this section maintains much of the information lost with the previous 
quantitation method (Figure 4-4). Therefore, these results suggest that loss of Rgl2 has 
no effect on autophagy.  
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Figure 4-5. Loss of Rgl2 has no effect on autophagosome maturation in MIA-PACA-2 
cells 
 
A. MIA-PACA-2 cells were infected with control, Rgl2, or RalB shRNA as well as a GFP-
RFP-LC3 construct. After three days of puromycin selection, cells were glucose starved 
for three hours and images were taken with a confocal microscope by Seth Winfree. The 
levels of Rgl2 and beta-actin were also measured using immunoblot analysis in samples 
plated in parallel. Images are representative of two experiments. 
 
B. Quantitation of the percent of mature autophagosomes per cell. The number of red 
and green vesicles was determined by exporting the images to ImageJ, individually 
selecting cells, setting a threshold for each channel, and using the software to 
determine the number of vesicles. A mature autophagosome was considered a vesicle 
that had red signal but no green signal. Data is representative of the combined data of 
two experiments.  Error bars represent standard deviation of the mean and p-values 
determined with a Student’s T-Test. 
 
C. Quantitation of the number of green vesicles. The number of green vesicles was 
determined using the same method described in B. Data is representative of the 
combined data of two experiments.  Error bars represent standard deviation of the 
mean and p-values determined with a Student’s T-Test. 
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 4.2.6 PDAC cells accumulate LC3-II during glucose starvation 
 
 We next measured endogenous LC3 as another method of determining if loss of 
Rgl2 has an effect on autophagy in PDAC cells. Because of the different levels of basal 
autophagy in different cell lines, however, we first just measured how glucose starvation 
affects LC3 levels in PDAC cells. During autophagy, LC3-I is lipid modified to generate 
LC3-II, then LC3-II is degraded with the contents of the autophagosome [96]. Therefore, 
by measuring LC3-II levels over the course of time one can track autophagy progression. 
To do this, we used HeLa cells as a technical control (since they had been used in [105]) 
in addition to the PDAC cell lines PANC1 and MIA-PACA-2. Each cell line was glucose 
starved for 0, 0.5, 3, 6, or 24 hrs and LC3 levels were measured using immunoblotting. 
After 24 hrs glucose starvation, LC3-II levels decreased in HeLa cells but increased in 
both the PDAC cell lines (Figure 4-6). These results are consistent with previously 
published data [138, 139]. Therefore, these results show that accumulation of LC3-II is a 
good marker of glucose starvation-induced autophagy in PDAC cells. 
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Figure 4-6. PDAC cells accumulate LC3-II during glucose starvation 
 
A. HeLa cells were starved for 0, 0.5, 3, 6, or 24 hrs. Lysates were harvested and LC3 and 
beta-actin levels were determined with immunoblot analysis. Blot is representative of 
two experiments. 
 
B. Quantification of A. All conditions normalized to beta-actin levels.  
 
C. The same assay from A. was performed using MIA-PACA-2 cells. Blot is representative 
of three experiments. 
 
D. Quantification of C. All conditions normalized to beta-actin levels. Error bars 
represent standard deviation of the mean. 
 
E. The same assay from A. was performed using PANC1 cells. Blot is representative of 
three experiments. 
 
F. Quantification of E. All conditions normalized to beta-actin levels. Error bars represent 
standard deviation of the mean. 
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4.2.7   Loss of Rgl2 and RalB do not significantly inhibit LC3-II accumulation 
during glucose starvation in PDAC cells  
 
 We next measured how loss of Rgl2 affects endogenous LC3-II levels. Previous 
published data reported that loss of RalB inhibits autophagy, so RalB shRNA was used as 
a positive control [105]. Another positive control used was Atg5 shRNA, a protein that 
mediates the elongation of the phagophore [95]. Our previous results showed that loss 
of Rgl2 has no effect on autophagy (Figure 4-5); however, that experiment was 
performed with highly expressed, exogenous, fluorescent LC3 which may have skewed 
the results. To look at endogenous LC3 levels, HeLa cells (to confirm results from 
previous studies) and the PDAC cells PANC1 and MIA-PACA-2 were infected with control, 
Rgl2, RalB, and Atg5 shRNAs [105]. The cells were then glucose starved for 24 hrs and 
LC3 levels were measured using immunoblotting. Loss of ATG5 decreased LC3-II loss in 
HeLa cells and slightly decreased LC3-II accumulation in the PDAC cell lines (Figure 4-7). 
An antibody against Atg5 was not available to ensure knockdown but the biological 
effect on LC3-II levels suggests it does work. Loss of Rgl2 and RalB surprisingly had no 
effect on LC3-II accumulation in the PDAC cell lines. These results further support the 
data presented in Chapter 4.2.5 to suggest loss of Rgl2 has no effect on autophagy in 
PDAC cells. 
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Figure 4-7. Loss of Rgl2 and RalB do not significantly inhibit LC3-II accumulation during 
glucose starvation in PDAC cells 
 
A. HeLa cells were infected with control, Rgl2, RalB, or Atg5 shRNA. After three days of 
puromycin selection, cells were glucose starved for three hours and lysates were 
harvested. The levels of LC3, RalB, Rgl2, and beta-actin were then measured using 
immunoblot analysis. Blots are representative of three experiments. 
 
B. Quantification of A. All conditions normalized to beta-actin levels. Error bars 
represent standard deviation of the mean and p-values determined with a Student’s T-
Test. 
 
C. The same assay from A. was performed using MIA-PACA-2 cells. Blot is representative 
of three experiments. 
 
D. Quantification of C. All conditions normalized to beta-actin levels. Error bars 
represent standard deviation of the mean. 
 
E. The same assay from A. was performed using PANC1 cells. Blot is representative of 
three experiments. 
 
F. Quantification of E. All conditions normalized to beta-actin levels. Error bars represent 
standard deviation of the mean. 
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4.2.8 Loss of Rgl2 and RalB do not significantly impact LC3 flux during glucose 
starvation in PDAC cells 
 
 As discussed before, LC3-II is both generated and degraded over the course of 
autophagy [96]. Because of this flux, it is a common practice to also measure the total 
accumulation of LC3-II when studying autophagy [140]. If an inhibitor is used to prevent 
LC3-II degradation, one can measure the rate of LC3-I to LC3-II conversion. We next used 
this method to determine how loss of Rgl2 may affect LC3-II accumulation. Also the 
results in Chapter 4.2.5 suggested that loss of RalB may be increasing rates of 
autophagy, and measuring LC3-II accumulation could confirm this. To test this, MIA-
PACA-2 and PANC1 cells were infected with control, Rgl2, or RalB shRNAs. The cells were 
then treated with CQ, an autophagy inhibitor, or vehicle and two control plates were 
starved for 24 hrs. As expected, CQ caused LC3-II to accumulate in both cell lines but 
loss of Rgl2 and RalB had no effect on this accumulation (Figure 4-8). Glucose starvation 
was used as a positive control to increase accumulation of LC3-II, and this was seen to a 
small degree in PANC1 cells. The combination of CQ and glucose starvation, however, 
was toxic to the MIA-PACA-2 cells, making LC3-II measurement difficult. These 
unexpected results may be due to the 24 hr CQ treatment time, which might have been 
excessively long. These results do suggest, however, that loss of Rgl2 and RalB have no 
significant effect on LC3 flux. 
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Figure 4-8. Loss of Rgl2 and RalB do not significantly impact LC3 flux during glucose 
starvation in PDAC cells 
 
A. MIA-PACA-2 cells were infected with control, Rgl2, or RalB shRNA. After three days of 
puromycin selection, cells were glucose starved and treated with chloroquine (CQ) for 
24 hours and lysates were harvested. The levels of LC3, RalB, Rgl2, and beta-actin were 
then measured using immunoblot analysis. Blots are representative of three 
experiments. 
 
B. Quantification of A. All conditions normalized to beta-actin levels. Error bars 
represent standard deviation of the mean and p-values determined with a Student’s T-
Test. 
 
C. The same assay from A. was performed using PANC1 cells. Blot is representative of 
three experiments. 
 
D. Quantification of C. All conditions normalized to beta-actin levels. Error bars 
represent standard deviation of the mean. 
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4.3 Discussion 
 
 It was previously reported that loss of RalB inhibits autophagy by preventing 
autophagosome formation [105]. These findings led us to hypothesize that loss of Rgl2 
would inhibit RalB activation and autophagy in PDAC cells, thereby increasing PDAC cell 
death. Loss of Rgl2 did in fact inhibit PDAC cell viability and increase cell death (Figures 
4-2 and 4-3). However, when we measured the effect of Rgl2 loss on number of dead 
cells during glucose starvation (Figure 4-3), glucose starvation did not have a synergistic 
effect with Rgl2 loss. This result suggests that the mechanism by which Rgl2 regulates 
cell death is independent of autophagy. Our microscopy experiments, furthermore, 
revealed that loss of Rgl2 does not significantly inhibit autophagosome number or 
maturation (Figure 4-5). Loss of Rgl2 also had no effect on endogenous LC3-II processing 
(Figures 4-7 and 4-8). These results suggest that loss of Rgl2 has no significant effect on 
autophagy in PDAC cells. The inability of loss of Rgl2 to inhibit autophagy could be 
because of several reasons. One could be that another RalGEF, besides Rgl2, is 
regulating autophagy. Recently published work found that RalGDS regulates RalB-
dependent autophagy in cardiomyocytes [141]. This work also showed that loss of 
RalGDS inhibits cardiomyocyte growth [141]. Our initial microscopy data suggested that 
loss of RalGDS has no effect on autophagy in PDAC cells, but this was a preliminary assay 
and may require further investigation. Loss of RalA has been shown to inhibit PDAC cell 
survival, therefore the loss of Rgl2-mediated inhibition of cell survival may be entirely be 
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due to RalA inhibition [50]. Therefore, RalB-dependent autophagy and cell growth may 
be regulated by another RalGEF in PDAC cells. 
As expected, loss of RalB did inhibit starvation-induced autophagosome 
reduction and maturation (Figure 4-5). These results from the microscopy data suggest 
that RalB does regulate autophagy in PDAC cells. RalB and Atg5 shRNAs were also used 
as positive controls while measuring endogenous LC3-II levels (Figure 4-7). As expected, 
loss of Atg5 inhibited LC3-II processing. Loss of RalB, on the other hand, did not affect 
LC3-II processing. These results are not consistent with the literature or even our own 
microscopy data. There are a few explanations that could account for this inconsistency. 
First of all, in the microscopy data we were measuring exogenously expressed LC3 while 
in the blotting data we were measuring endogenous LC3. Endogenous levels of LC3 are 
always in flux, are variable between tissues, and do not always correlate with autophagy 
activity, therefore LC3-II levels can be an inconsistent measure of autophagy [140]. Also, 
deletion of some autophagy proteins (such as Beclin1) will not necessarily inhibit LC3-II 
formation [142]. Because of the dynamic expression of LC3, exogenously expressed LC3 
is a more reliable marker of autophagic flux [140]. Another possibility for the 
inconsistent results may be due to how the PDAC cells were starved. The previous 
published data showed that loss of RalB inhibited autophagy induced by combined 
glucose and amino acid starvation [105]. To describe a more specific autophagy 
pathway, we starved the cells of only glucose. Recently published data, however, 
suggests that glucose starvation does not induce prosurvival autophagy [143]. Even 
more surprisingly, this paper suggests that glucose starvation does not actually increase 
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autophagic flux. Even though this work is somewhat controversial, it does suggest that 
there is a distinction between autophagy induced by glucose compared to that induced 
by amino acid starvation. Therefore, RalB and Rgl2 may regulate autophagy induced by 
amino acid starvation but not glucose starvation. In conclusion, while loss of Rgl2 does 
increase PDAC cell death, it does not significantly inhibit autophagy. 
 
4.4 Future directions 
 
 Our findings, that loss of Rgl2 inhibits PDAC cell survival but has no significant 
effect on autophagy, can be expanded upon with a number of further experiments. 
Firstly, as discussed in a recent paper, glucose starvation is a controversial method of 
inducing autophagy [143]. Therefore, it would be important to compare how starving 
PDAC cells of glucose and amino acids differently induce autophagy. All that would be 
required for these experiments would be media depleted of amino acids and media 
without glucose. This comparison could be done in the survival assays as well as the LC3 
microscopy and endogenous LC3 assays. These experiments would show if Rgl2 and RalB 
differently regulate amino acid- or glucose-dependent autophagy pathways. Another 
possible experiment would be to compare how loss of the different RalGEFs affects 
autophagy. Even though it has been shown that Rgl2 and RalGDS are the most highly 
expressed RalGEFs in PDAC cells, the other RalGEFs may have increased activity in spite 
of low expression [50]. Further experiments could also address whether loss of the 
RalGEFs inhibit cell survival proportionally with autophagy inhibition. For example, loss 
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of RalGDS may inhibit autophagy and cell survival while loss of Rgl2 only inhibits cell 
survival. These experiments would help reveal if there is a link between RalB-mediated 
autophagy and survival. A link between these phenomena and the Ral proteins could 
also be drawn using constitutively active RalA and RalB. For instance, the increase in cell 
death caused by loss of Rgl2 may be restored with a constitutively active RalA but not 
RalB. Using these constructs could further elucidate the signaling pathways that link the 
loss of a RalGEF and the biological response. Also, our hypothesis was dependent on the 
constitutive activity of KRas and RalB-dependent autophagy. Further experiments with 
cells with wild type KRas could help us determine if Rgl2 is indeed crucial for cell survival 
under these conditions. Experiments such as these would help to further describe the 
relationship between the different RalGEFs and Rals and potentially draw a connection 
between RalB-dependent autophagy and survival.  
  
94 
 
APPENDIX – NUCLEOTIDE SEQUENCES 
shRNA Sequence 
Control CCTAAGGTTAAGTCGCCCTCG 
Atg5 CCGGCCTGAACAGAATCATCCTTAACTCGAGTTAAGGATGATTCTGTTCAGGTTTTTTG 
RalB CCGGCGTGATGAGTTAAAGTTGTATCTCGAGATACAACTTTAACTCATCACGTTTTTG 
RalGDS CCGGTCTACTGCCAACTATGACTTTCTCGAGAAAGTCATAGTTGGCAGTAGATTTTTG 
Rgl2 GCAGTGTCTATAAGAGCATTT 
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